Editas Medicine (EDIT) EBIT (2015 - 2025)

Editas Medicine (EDIT) has reported EBIT for 11 consecutive years, with -$24.5 million the latest figure, recorded in Q3 2025.

• In Q3 2025, EBIT rose 62.62% year-over-year to -$24.5 million; the TTM figure through Sep 2025 stood at -$198.8 million (up 12.99% YoY), while the FY2024 annual figure was -$251.2 million, down 48.45% from the prior year.
• EBIT rose to -$24.5 million in Q3 2025 per EDIT's latest filing, from -$51.5 million in the prior quarter.
• Across five years, EBIT topped out at -$24.0 million in Q4 2023 and bottomed at -$76.2 million in Q1 2025.
• Historically, EBIT has averaged -$52.2 million across 5 years, with a median of -$51.5 million in 2025.
• Annual changes were most pronounced in 2021 — EBIT slumped 536.68% — and 2025, when it soared 62.62%.
• Editas Medicine's EBIT stood at -$41.6 million in 2021, then tumbled by 52.48% to -$63.4 million in 2022, then surged by 62.23% to -$24.0 million in 2023, then sank by 94.45% to -$46.6 million in 2024, then surged by 47.31% to -$24.5 million in 2025.
• Business Quant data shows EDIT's EBIT at -$24.5 million in Q3 2025, -$51.5 million in Q2 2025, and -$76.2 million in Q1 2025.